{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:57:36Z","timestamp":1782899856182,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Opa interacting protein 5 (<jats:italic>OIP5<\/jats:italic>), overexpressed in some types of human cancers, has been reported to be associated with the carcinogenesis of human cancer. However, its contribution to cancer immunity remains unknown. Furthermore, the relationship between <jats:italic>OIP5<\/jats:italic> and cancer immunity remains uncertain. In our research, we explored the different expression of <jats:italic>OIP5<\/jats:italic> between 539 ccRCC and 72 normal renal tissues base on TCGA data set. We analyzed the associations between OIP5 expression with ccRCC progression and survival. Next, we compared immune cell profiles in cancer tissues and normal tissues in the Cancer Genome Atlas (TCGA) ccRCC cohort. We found that the level of immune cell infiltration was correlated with the copy number of <jats:italic>OIP5<\/jats:italic> gene in ccRCC. The effect of <jats:italic>OIP5<\/jats:italic> on immune activity was verified by Gene Set Enrichment Analysis of RNA-seq data from 32 ccRCC cell lines in the public database. Moreover, a pathway enrichment analysis of 49 <jats:italic>OIP5<\/jats:italic>-associated immunomodulators demonstrated the involvement of the T cell receptor signaling pathway, the JAK-STAT signaling pathway, the NF-kappa B signaling pathway and the primary immunodeficiency pathway. In addition, using <jats:italic>OIP5<\/jats:italic>-associated immunomodulators, we constructed multiple-gene risk prediction signatures using the Cox regression model. Our results provided insights into the role of <jats:italic>OIP5<\/jats:italic> in tumor immunity and revealed that <jats:italic>OIP5<\/jats:italic> may be a potential immunotherapeutic target for ccRCC. Designated immune signature is a promising prognostic biomarker in ccRCC.<\/jats:p>","DOI":"10.3389\/fimmu.2022.805552","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T06:49:13Z","timestamp":1644907753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates"],"prefix":"10.3389","volume":"13","author":[{"given":"Mancheng","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaopeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic Therapy for Metastatic Renal-Cell Carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000436988","article-title":"Immunotherapies in Early and Advanced Renal Cell Cancer","volume":"42","author":"Kasenda","year":"2015","journal-title":"Prog Tumor Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21411","article-title":"Treatment of Renal Cell Carcinoma: Current Status and Future Directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0066","article-title":"Genomic Approaches to Understanding Response and Resistance to Immunotherapy","volume":"22","author":"Braun","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00670.x","article-title":"Using the Yeast Two-Hybrid System to Identify Human Epithelial Cell Proteins That Bind Gonococcal Opa Proteins: Intracellular Gonococci Bind Pyruvate Kinase via Their Opa Proteins and Require Host Pyruvate for Growth","volume":"27","author":"Williams","year":"1998","journal-title":"Mol Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy037","article-title":"Cancer-Testis Specific Gene OIP5: A Down-Stream Gene of E2F1 That Promotes Tumorigenesis and Metastasis in Glioblastoma by Stabilizing E2F1 Signaling","volume":"20","author":"He","year":"2018","journal-title":"Neuro Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2485-4","article-title":"Opa Interacting Protein 5 Acts as an Oncogene in Bladder Cancer","volume":"143","author":"He","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.11.4623","article-title":"Cancer\/Testis OIP5 and TAF7L Genes Are Up-Regulated in Breast Cancer","volume":"16","author":"Mobasheri","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2010.43.5.349","article-title":"OIP5 Is a Highly Expressed Potential Therapeutic Target for Colorectal and Gastric Cancers","volume":"43","author":"Chun","year":"2010","journal-title":"BMB Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2013.03.008","article-title":"Expression of Opa Interacting Protein 5 (OIP5) Is Associated With Tumor Stage and Prognosis of Clear Cell Renal Cell Carcinoma","volume":"115","author":"Gong","year":"2013","journal-title":"Acta Histochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust Enumeration of Cell Subsets From Tissue Expression Profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells With CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: An Integrated Repository Portal for Tumor\u2013Immune System Interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki475","article-title":"WebGestalt: An Integrated System for Exploring Gene Sets in Various Biological Contexts","volume":"33","author":"Zhang","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz401","article-title":"WebGestalt 2019: Gene Set Analysis Toolkit With Revamped UIs and APIs","volume":"47","author":"Liao","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jbi.2011.02.005","article-title":"An Empirical Approach to Model Selection Through Validation for Censored Survival Data","volume":"44","author":"Choi","year":"2011","journal-title":"J BioMed Inform"},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","article-title":"New Horizons in Tumor Microenvironment Biology: Challenges and Opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor Microenvironment and Therapeutic Response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42998","article-title":"Modulation of Tumor Microenvironment for Immunotherapy: Focus on Nanomaterial-Based Strategies","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e000447","DOI":"10.1136\/jitc-2019-000447","article-title":"Identification and Validation of Dichotomous Immune Subtypes Based on Intratumoral Immune Cells Infiltration in Clear Cell Renal Cell Carcinoma Patients","volume":"8","author":"Xiong","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4604","article-title":"Emerging Role of Combination Immunotherapy in the First-Line Treatment of Advanced Renal Cell Carcinoma: A Review","volume":"5","author":"George","year":"2019","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det072","article-title":"Leptin Suppresses Anti-Mullerian Hormone Gene Expression Through the JAK2\/STAT3 Pathway in Luteinized Granulosa Cells of Women Undergoing IVF","volume":"28","author":"Merhi","year":"2013","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.805552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T06:49:15Z","timestamp":1644907755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.805552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.805552"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.805552","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"article-number":"805552"}}